Medicenna and Fondazione Melanoma Onlus Collaborate to Advance MDNA11 Before First-Line Therapy in a Randomized Neoadjuvant Combination Trial, "NEO-CYT", in High-Risk, Surgically Resectable Stage III Melanoma Life Science Investing
GH Research Reports Third Quarter 2025 Financial Results and Provides Business Updates Life Science Investing
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week Life Science Investing
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 for the Treatment of PH-HFpEF Life Science Investing
C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights Life Science Investing
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics Life Science Investing
Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy Life Science Investing
Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Life Science Investing
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 Life Science Investing
Acadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview Life Science Investing
